2 ms·
You likely don’t need a standard phase three trial. If you are within the phase 1 safety dosages (that’s the data you’re using under 505(b)(2) anyway) you can
by gumby 5y ago
You likely don’t need a standard phase three trial. If you are within the phase 1 safety dosages (that’s the data you’re using under 505(b)(2) anyway) you can just do a smaller study. Power it as high as you want/need. Typically any physician can do such a study. Doctors can read your paper on the study and decide whether to use the therapy you studied.
- savvak 5y agoYes, it may be possible to update standard of care with a robust Phase 2 RCT that convinces doctors, especially for a pilot. Phase 3 trials for a repurposed generic would be more expensive, but a new label indication would provide further incentives to update SoC because doctors and pharmacies would be less exposed to liability for prescribing off-label.